Overview
Mycoses encompass a broad range of fungal infections affecting various tissues, often exacerbated by systemic diseases, immune deficiencies, and environmental factors 4.Diagnosis
Microscopic Examination: KOH preparations and culturing remain foundational but are complemented by dermatohistology 1.
Molecular Techniques: DNA-based methods, such as PCR, enhance sensitivity and specificity, offering rapid diagnosis within 24-48 hours 1.
Guideline Development: Regular updates through expert consensus processes ensure diagnostic standards evolve with medical advancements 2.Management
First-Line Treatments: Azoles (e.g., itraconazole, fluconazole) and allylamines are highly effective 4.
Monitor for Interactions: Careful monitoring of concomitant medications, especially calcium channel blockers, statins, and clarithromycin with itraconazole, to prevent drug-drug interactions 3.
Personalized Medicine: Consideration of point-of-care tests for rapid diagnosis and tailored treatment plans 1.Special Populations
Comorbidities: Patients with diabetes, obesity, hormonal disorders, immune deficiencies, and those on immunosuppressive medications are at higher risk and require vigilant management 4.
Drug Interactions: Special attention to potential drug interactions in elderly patients and those with multiple comorbidities, particularly with itraconazole 3.Key Recommendations
Utilize molecular techniques like PCR for rapid and accurate diagnosis of mycoses (Evidence: Strong 1).
Regularly update diagnostic guidelines through expert consensus to reflect advancements in personalized medicine (Evidence: Expert opinion 2).
Monitor for and manage potential drug interactions, especially with azole antifungals like itraconazole, in patients with multiple comorbidities (Evidence: Moderate 3).References
1 Wiegand C, Bauer A, Brasch J, Nenoff P, Schaller M, Mayser P et al.. Are the classic diagnostic methods in mycology still state of the art?. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2016. link
2 Seebacher C, Korting HC. Dermatomycological guidelines: 10 years of experience in Germany. Mycoses 2007. link
3 Galatti L, Mazzaglia G, Greco A, Sessa E, Cricelli C, Schito GC et al.. Co-prescriptions with itraconazole and fluconazole as a signal for possible risk of drug-drug interactions: a four-year analysis from Italian general practice. Pharmacoepidemiology and drug safety 2007. link
4 Warmińska J, Kur A, Bartosińska J, Jermak A, Kowal A, Wypyska G et al.. Mycoses--prophylaxis and treatment. Annales Universitatis Mariae Curie-Sklodowska. Sectio D: Medicina 2003. link